Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles

Table 2 Micropaticles and laboratory data after treatment in OR group and PD group

Variables	OR (n = 60)	PD (n = 26)	P
Neutrophils, ×10⁹/L, median(IQR)	3.62 [2.70,4.50]	4.30 [2.93,5.35]	0.232^#
Platelets, ×10⁹/L, median(IQR)	205 [154,258]	196 [160,281]	0.807^#
NLR, median(IQR)	2.43 [1.62,3.23]	3.37 [1.75,7.04]	0.029^#
LDH, U/L, median(IQR)	166 [142,200]	188 [169,240]	0.004^#
CEA, ng/ml, median(IQR)	2.85 [1.95,12.76]	8.72 [3.29,50.13]	0.026^#
CYFRA-211, ng/ml, median(IQR)	3.15 [2.14,4.08]	4.54 [3.30,8.11]	< 0.0001^#
SCC, ng/ml, median(IQR)	1.10 [0.93,1.58]	1.05 [0.68,1.93]	0.491^#
Micropaticals, events/μL, median(IQR)
total MPs	1975 [1090,3120]	3590 [1492,4405]	0.006^#
NMPs	118 [66,229]	248 [116,338]	0.002^#
PMPs	56 [31,109]	157 [93,282]	<0.0001^#

NLR neutrophil-lymphocyte ratio, LDH lactate dehydrogenase, CEA carcino-embryonic antigen, CYFRA-211 Cytokeratin 19 fragment, SCC Squamous cell carcinoma antigen, MPs microparticals, NMPs neutrophil-derived microparticals, PMPs platelet-derived microparticles
^#Mann-Whitney U test

ISSN: 1471-2407